Stock NWBO NORTHWEST BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Northwest Biotherapeutics, Inc.

Equities

NWBO

US66737P6007

Market Closed - OTC Markets
Other stock markets
 01:29:55 25/05/2024 am IST 		5-day change 1st Jan Change
0.44 USD -2.65% Intraday chart for Northwest Biotherapeutics, Inc. -4.14% -37.23%
10/05 Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
21/03 Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation
MT
Northwest Biotherapeutics Reports Positive Top-Line Results from Phase 3 Trial of DCVax®-L for Glioblastoma
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Northwest Biotherapeutics Announces Commencement of Cancer Vaccine Production At Its Sawston, UK Facility
CI
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing at Sawston, UK Facility
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Northwest Biotherapeutics Announces Hta License Issued and Mhra Inspection Conducted for Sawston, UK Facility
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Northwest Biotherapeutics Announces UK Manufacturing Facility & Phase III Trial Updates
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NWBO Stock
  4. News Northwest Biotherapeutics, Inc.
  5. Highlights